Home > Publications database > European practice on neurovascular late effects after pediatric radiotherapy: considerations on dose planning and follow-up - a HARMONIC/SIOPE ROWG survey. > print

001     301549
005     20250524113308.0
024 7 _ |a 10.2340/1651-226X.2025.43028
|2 doi
024 7 _ |a pmid:40402041
|2 pmid
024 7 _ |a 0284-186X
|2 ISSN
024 7 _ |a 0348-5196
|2 ISSN
024 7 _ |a 0567-8056
|2 ISSN
024 7 _ |a 0567-8064
|2 ISSN
024 7 _ |a 1100-1704
|2 ISSN
024 7 _ |a 1651-226X
|2 ISSN
024 7 _ |a 1651-2499
|2 ISSN
037 _ _ |a DKFZ-2025-01070
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Toussaint, Laura
|b 0
245 _ _ |a European practice on neurovascular late effects after pediatric radiotherapy: considerations on dose planning and follow-up - a HARMONIC/SIOPE ROWG survey.
260 _ _ |a Abingdon
|c 2025
|b Taylor & Francis Group
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1748004753_17488
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a The risk of developing neurovascular late effects after radiotherapy is an area of concern when treating pediatric brain tumor patients. However, knowledge is sparse regarding best practice for clinical management during the radiotherapy (RT) planning process and follow-up examinations. This study therefore aimed at mapping how the risk of neurovascular late effects is considered for pediatric brain or skull base tumor patients treated with radiotherapy in Europe.Two web-based surveys ‑ a RT and a pediatric oncology (PO) survey - were distributed to members of the SIOPE radiotherapy working group or PANCARE and SIOPE brain tumor group, respectively.The RT survey was completed by 47 participants from 18 different European countries and the PO survey by 33 participants (mostly pediatric (neuro)oncologists) from 15 countries. Overall, the answers highlighted that neurovascular late effects are currently not well included in European clinical practice, neither at the time of radiotherapy nor in the follow-up process.There is a need for raising general awareness about the topic, as well as for potential risk-stratified prevention measures and follow-up guidelines.
536 _ _ |a 899 - ohne Topic (POF4-899)
|0 G:(DE-HGF)POF4-899
|c POF4-899
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Europe
|2 MeSH
650 _ 2 |a Child
|2 MeSH
650 _ 2 |a Follow-Up Studies
|2 MeSH
650 _ 2 |a Brain Neoplasms: radiotherapy
|2 MeSH
650 _ 2 |a Radiotherapy Planning, Computer-Assisted: methods
|2 MeSH
650 _ 2 |a Radiation Injuries: etiology
|2 MeSH
650 _ 2 |a Radiation Injuries: prevention & control
|2 MeSH
650 _ 2 |a Radiation Injuries: epidemiology
|2 MeSH
650 _ 2 |a Surveys and Questionnaires
|2 MeSH
650 _ 2 |a Radiotherapy Dosage
|2 MeSH
650 _ 2 |a Skull Base Neoplasms: radiotherapy
|2 MeSH
650 _ 2 |a Practice Patterns, Physicians': statistics & numerical data
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Male
|2 MeSH
700 1 _ |a Tram Henriksen, Louise
|b 1
700 1 _ |a Van Beek, Karen
|b 2
700 1 _ |a Bolle, Stephanie
|b 3
700 1 _ |a Demoor-Goldschmidt, Charlotte
|b 4
700 1 _ |a Gains, Jenny
|b 5
700 1 _ |a Høyer, Morten
|b 6
700 1 _ |a Janssens, Geert O
|b 7
700 1 _ |a Kortmann, Rolf-Dieter
|b 8
700 1 _ |a Martins Pedro, Catia
|b 9
700 1 _ |a Timmermann, Beate
|0 P:(DE-HGF)0
|b 10
700 1 _ |a Scheinemann, Katrin
|b 11
700 1 _ |a Lassen-Ramshad, Yasmin
|b 12
773 _ _ |a 10.2340/1651-226X.2025.43028
|g Vol. 64, p. 703 - 707
|0 PERI:(DE-600)1492623-4
|p 703 - 707
|t Acta oncologica
|v 64
|y 2025
|x 0284-186X
909 C O |o oai:inrepo02.dkfz.de:301549
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 10
|6 P:(DE-HGF)0
913 1 _ |a DE-HGF
|b Programmungebundene Forschung
|l ohne Programm
|1 G:(DE-HGF)POF4-890
|0 G:(DE-HGF)POF4-899
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-800
|4 G:(DE-HGF)POF
|v ohne Topic
|x 0
914 1 _ |y 2025
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2024-12-11
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2024-08-13T06:17:08Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2024-08-13T06:17:08Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2024-08-13T06:17:08Z
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
|d 2024-08-13T06:17:08Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2024-12-11
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-11
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-11
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b ACTA ONCOL : 2022
|d 2024-12-11
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2024-12-11
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2024-12-11
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2024-12-11
920 1 _ |0 I:(DE-He78)ED01-20160331
|k ED01
|l DKTK Koordinierungsstelle Essen/Düsseldorf
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)ED01-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21